BPC-157 vs KPV
Both are sold for gut inflammation, often together, and both rest mainly on rat and mouse studies. BPC-157 has a few small human reports, including one ulcerative colitis trial known only from a 2005 abstract; KPV has never been tested in people.
- BPC-157
- Preclinical1–2× daily
- KPV
- PreclinicalOnce daily
- Head-to-head trials
- None published
The short answer
BPC-157 is a 15-amino-acid peptide based on a protein in gastric juice; in rats it’s linked to new blood vessel growth and faster healing of the gut and other tissues, through a target nobody has identified. KPV is the last three amino acids of alpha-MSH, a hormone with anti-inflammatory effects; in cell and mouse studies it’s carried into gut lining and immune cells, where it turns down inflammatory signals. Both are injected or swallowed for gut problems, and both are in the KLOW blend.
Human evidence is thin for BPC-157 and absent for KPV. Reviewing BPC-157 for ulcerative colitis, a long-term inflammation of the colon, FDA found one trial, reported only as a 2005 conference abstract: 53 people took an 80 mg enema or placebo daily for 2 weeks, and the difference between groups could have been chance. FDA found no human data at all for KPV. Even so, in July 2026 FDA’s advisory committee voted 8 to 6 to recommend both for pharmacy compounding, against FDA staff advice.
At a glance
| Field | BPC-157Body Protection Compound-157, PL 14736 | KPVLys-Pro-Val, α-MSH (11–13) |
|---|---|---|
| Evidence | Preclinical | Preclinical |
| Class | Tissue-repair peptide | Anti-inflammatory peptide |
| Approval | Not approved as a drug in the US or EU. | Not approved as a drug in the US or EU. |
| Sport (WADA 2026) | Banned in sport | Likely banned in sport |
| Common dose | 250–500 mcg, 1–2× daily | 200–500 mcg daily |
| Frequency | 1–2× daily | Once daily |
| Cycle | 6 weeks on, 3 off | 8 weeks on, 8 off |
| Route | Subcutaneous injection (community); oral for gut-focused use | Subcutaneous injection or oral (community) |
| Half-life | under 30 minutes Animal | – |
| Typical draw | 10 units5 mg with 2 mL, 250 mcg | 20 units5 mg with 2 mL, 500 mcg |
| Vial sizes or form | 5, 10 mg | 5, 10 mg |
| Human studies | 3 listedLargest: 16 people (2021) | None found |
| Main cautions |
|
|
| Open BPC-157 | Open KPV |
Doses shown are what labels, trials or community reports reference, not recommendations. Each compound’s page has the full detail and sources.
Key differences
What they are
BPC-157: GEPPPGKPADDAGLV, 15 amino acids, based on a gastric juice protein. KPV: Lys-Pro-Val, 3 amino acids, the tail end (residues 11–13) of alpha-melanocyte-stimulating hormone (alpha-MSH).
How they work
AnimalNeither has a confirmed target. In rat and cell studies BPC-157 is linked to new blood vessel growth and nitric oxide signaling. In cell and mouse studies KPV enters gut lining and immune cells through PepT1, a transporter for very small peptides, and damps NF-kB, a switch that turns on inflammatory messengers. FDA concluded the melanocortin receptors its parent hormone uses are unlikely to be its target.
Gut studies in animals
AnimalBPC-157: in rats, by mouth or injection, it sped healing of surgically made colon fistulas (abnormal channels from the bowel) and reduced stomach and intestinal damage from high doses of NSAID painkillers such as aspirin. KPV: given in drinking water, it reduced chemically induced colitis in mice, and another group saw faster recovery in two mouse colitis models.
Human evidence
TrialBPC-157: two enema trials known only from conference abstracts (32 healthy people, then 53 with ulcerative colitis) and three small published reports outside the gut: knee injections, bladder injections and a 2-person IV pilot. None gave it by mouth or under the skin. KPV: no human data by any route.
Typical community use
CommunityBPC-157: 250–500 mcg once or twice a day, injected or swallowed, often for 4–8 weeks. KPV: 200–500 mcg injected once a day (500 mcg most cited), or 200 mcg–1 mg a day by mouth, often for 8 weeks. None of these doses has been tested in a human study.
Side effects and cautions
Users of both report injection-site redness and occasional nausea. Neither has human safety data in pregnancy. BPC-157 promotes blood vessel growth in animals, a theoretical concern with active or past cancer. KPV damps inflammatory signaling in animals and hasn’t been studied alongside immune-suppressing drugs.
Status
Neither is approved anywhere. Both compounding nominations were withdrawn, but FDA reviewed them anyway, BPC-157 for ulcerative colitis and KPV for wounds and inflammatory conditions, and advised against both. On July 23, 2026 its advisory committee voted 8 to 6 (1 abstaining) to recommend each. In sport, BPC-157 is banned by name under WADA’s S0 rule for unapproved drugs, and KPV falls under the same rule.
Head-to-head studies
Taking them together
Their pages list them as a common pairing. That reflects community practice, not trials.
Common gut pairing: KPV to calm inflammation, BPC-157 to support repair of the gut lining.
Open them in the stack check for sport status and one combined tracking checklist.
Questions
What is the difference between BPC-157 and KPV?
BPC-157 is a 15-amino-acid peptide based on a protein in gastric juice; in rats it’s linked to new blood vessel growth and faster healing of the gut and other tissues, through a target nobody has identified. KPV is the last three amino acids of alpha-MSH, a hormone with anti-inflammatory effects; in cell and mouse studies it’s carried into gut lining and immune cells, where it turns down inflammatory signals. Both are injected or swallowed for gut problems, and both are in the KLOW blend.
Do BPC-157 or KPV help ulcerative colitis or Crohn’s disease?
There’s no good human evidence for either. BPC-157’s only colitis trial, a 2-week enema study in 53 people reported as a 2005 conference abstract, didn’t show a clear difference from placebo, and FDA judged the data inadequate. KPV has never been tested in people. Both reduced colitis or gut injury in rodents. FDA noted that several approved drugs treat ulcerative colitis.
Can BPC-157 and KPV be taken by mouth?
Community guides use both orally for gut problems, BPC-157 at 250–500 mcg and KPV at 200 mcg–1 mg a day, but no human study has tested either taken by mouth. The idea comes from rodents: KPV in drinking water reduced colitis in mice, and oral BPC-157 sped colon fistula healing in rats. A small trial of oral BPC-157 in healthy volunteers was registered in 2015, and no results were ever posted.
Can BPC-157 and KPV be taken together?
No overlap is documented. They’re a common pairing in community practice: common gut pairing: KPV to calm inflammation, BPC-157 to support repair of the gut lining. No published study has tested them together.
Which has more evidence in people, BPC-157 or KPV?
BPC-157 isn’t approved anywhere and rests mainly on cell and animal studies; its page lists 3 key human studies. KPV isn’t approved anywhere and rests mainly on cell and animal studies; its page lists no published human studies. They haven’t been compared directly in a published trial.
Are BPC-157 and KPV banned in sport?
BPC-157 is banned at all times. KPV is likely banned under WADA’s S0 rule for unapproved drugs. This follows the WADA 2026 Prohibited List; athletes should confirm with their anti-doping organization.
Sources
- FDA briefing document: BPC-157-related bulk drug substances, Pharmacy Compounding Advisory Committee (July 2026)
- FDA briefing document: KPV-related bulk drug substances, Pharmacy Compounding Advisory Committee (July 2026)
- Dalmasso et al., PepT1-mediated KPV uptake reduces intestinal inflammation (Gastroenterology 2008) PMID 18061177
- Kannengiesser et al., KPV in mouse models of inflammatory bowel disease (Inflamm Bowel Dis 2008) PMID 18092346
- PCO-02 (BPC-157) phase 1 safety and pharmacokinetics study of oral tablets in healthy volunteers: ClinicalTrials.gov registry entry NCT02637284